183 filings
Page 5 of 10
8-K
zy6o9xx53 dd26d1x
18 Mar 21
AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
7:06am
8-K
rezyjhd3km2 cn6zoxeu
8 Feb 21
Regulation FD Disclosure
7:57am
8-K
bv30bi4 0qw4
11 Jan 21
Regulation FD Disclosure
7:01am
8-K
ug6sblp
20 Nov 20
AVROBIO Announces Proposed Public Offering of Common Stock
4:08pm
424B5
sbsfmfquiw1wqoc
20 Nov 20
Prospectus supplement for primary offering
4:03pm
424B5
ckj2guejz
19 Nov 20
Prospectus supplement for primary offering
4:15pm
8-K
jgv1aw771qcutcd4ad
17 Nov 20
Other Events
9:07am
8-K
0l0 8vb4nb8
17 Nov 20
Three months post-gene therapy, first patient in Gaucher trial shows reductions in the toxic metabolite
7:39am
8-K
9bjitm03 t1
5 Nov 20
AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update
7:18am
8-K
op2cxe
21 Oct 20
AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
8:19am
8-K
lp43 nwc8c
6 Oct 20
Regulation FD Disclosure
8:29am
8-K
lmw1 b6tni
5 Oct 20
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
7:10am
S-8
ce1p h9u2w
6 Aug 20
Registration of securities for employees
7:28am
8-K
o1zwvohf xxc2cds0hpg
6 Aug 20
AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update
7:07am
8-K
ceb fpxat64
6 Jul 20
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
7:35am
8-K
doowh2bye
16 Jun 20
Regulation FD Disclosure
8:24am
8-K
6ad42 by35yyi2r
9 Jun 20
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
s0vp7hjy iafpr
14 May 20
Regulation FD Disclosure
7:05am